| 79.3 -4.27 (-5.11%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 96.39 |
1-year : | 100.43 |
| Resists | First : | 82.52 |
Second : | 85.98 |
| Pivot price | 81.31  |
|||
| Supports | First : | 76.92 |
Second : | 64 |
| MAs | MA(5) : | 82.22 |
MA(20) : | 80.72 |
| MA(100) : | 83.02 |
MA(250) : | 89.41 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 53.5 |
D(3) : | 61.9 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 103.76 | Low : | 72.65 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MDT ] has closed above bottom band by 23.1%. Bollinger Bands are 5.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 82.04 - 82.59 | 82.59 - 83.04 |
| Low: | 77.93 - 78.46 | 78.46 - 78.9 |
| Close: | 78.53 - 79.38 | 79.38 - 80.1 |
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
Tue, 14 Jul 2026
Is Medtronic PLC (MDT) a Bargain After 5.1% Drop? GF Value Says Undervalued - GuruFocus
Tue, 14 Jul 2026
Baird Adjusts Price Target on Medtronic to $91 From $85, Maintains Neutral Rating - marketscreener.com
Mon, 13 Jul 2026
MDT Stock Quote Price and Forecast - CNN
Sat, 11 Jul 2026
Medtronic PLC (XSWX:MDT) Stock Price, Trades & News - GuruFocus
Fri, 10 Jul 2026
Medtronic gains on coverage hopes for renal denervation (MDT) - Seeking Alpha
Fri, 10 Jul 2026
Medtronic: Guidance Built To Be Beaten - Buy - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1,280 (M) |
| Shares Float | 1,280 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 89.6 (%) |
| Shares Short | 19,090 (K) |
| Shares Short P.Month | 16,760 (K) |
| EPS | 3.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 38.63 |
| Profit Margin | 13.1 % |
| Operating Margin | 22 % |
| Return on Assets (ttm) | 4.9 % |
| Return on Equity (ttm) | 9.8 % |
| Qtrly Rev. Growth | 9.8 % |
| Gross Profit (p.s.) | 18.55 |
| Sales Per Share | 28.4 |
| EBITDA (p.s.) | 7.89 |
| Qtrly Earnings Growth | 18.2 % |
| Operating Cash Flow | 7,330 (M) |
| Levered Free Cash Flow | 4,630 (M) |
| PE Ratio | 21.26 |
| PEG Ratio | 1.6 |
| Price to Book value | 2.05 |
| Price to Sales | 2.79 |
| Price to Cash Flow | 13.84 |
| Dividend | 0.72 |
| Forward Dividend | 0 |
| Dividend Yield | 0.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|